" class="no-js "lang="en-US"> Sixfold Bioscience - Medtech Alert
Monday, October 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Sixfold Bioscience | Pharmtech Focus

Sixfold Bioscience

About Sixfold Bioscience

Sixfold Bioscience

Sixfold Bioscience is an award-winning, Y Combinator and venture-backed, preclinical-stage biotech based in London. Founded by experienced researchers from Cambridge Univeristy and London’s Francis Crick Institute, Sixfold develops next-generation in vivo delivery systems for RNA therapeutics.

Related Story

Fundraising

 Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing | Pharmtech Focus

Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing

December 3 2021

Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery […]